Share this page!

Kai Kupferschmidt Profile picture
Twitter logo
10 May, 4 tweets, 3 min read
Norway’s expert committee „does not recommend the inclusion of vaccines based on adenoviral vectors in the national vaccination program“

Should not come as a surprise to those who have followed @GretchenVogel1 and my reporting

H/t @Sciencenorwayno
regjeringen.no/contentassets/…
@GretchenVogel1 @Sciencenorwayno I have made the point again and again that his is about context.
In this case on top of low infection rates (see page 9):
- mRNA vaccines are becoming available faster in Norway
- 2nd dose of mRNA now to be given after 12 weeks, so more people will get first dose faster.
@GretchenVogel1 @Sciencenorwayno If the context changes, decision may too:
Recommendation is "based on the level of knowledge we have at present… Changes in infection rates, new virus mutants, unforeseen problems with vaccine deliveries and new information about side effects could lead to other conclusions"
@GretchenVogel1 @Sciencenorwayno Also note that diagnostics and treatment of #TTS played a role here:
“...in particular the measurement of antibodies to platelets, is not readily available or dimensioned for high-throughput screening. As of today, any treatment is complicated and has an uncertain effect."

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Kai Kupferschmidt

Kai Kupferschmidt Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @kakape

Kai Kupferschmidt Profile picture
12 May
The most comprehensive review of how the world responded to #covid19 and how to prevent the next pandemic was published today.
It will likely be the basis of discussions in coming months and years and so I read it for you.

Story here, thread to come:
sciencemag.org/news/2021/05/t…
Who wrote the report?
This is the Independent Panel for Pandemic Preparedness and Response (IPPPR), established last year in response to a resolution of the World Health Assembly.
It consists of 13 members led by @HelenClarkNZ and @MaEllenSirleaf. Image
@HelenClarkNZ @MaEllenSirleaf (To be completely transparent:
I was actually interviewed by this panel in February but only about the communication aspects of the pandemic. I have no other involvement with this report or the panel.)
Read 8 tweets
Kai Kupferschmidt Profile picture
10 May
"Globally, we are now seeing a plateauing in the number of #COVID19 cases and deaths, with declines in most regions”, says @DrTedros at @WHO presser. "But it’s an unacceptably high plateau, with more than 5.4 million reported #covid19 cases and almost 90.000 deaths last week."
@DrTedros @WHO “We've been here before”, says @DrTedros. “Over the past year, many countries have experienced a declining trend in cases and deaths, relaxing public health and social measures too quickly, and individuals have laid down their guard, only for those hard won gains to be lost."
@DrTedros @WHO "We are still in a perilous situation”, says @DrTedros.
"The spread of variants, increased social mixing, the relaxation of public health and social measures and inequitable vaccination, are all driving transmission."
Read 5 tweets
Kai Kupferschmidt Profile picture
7 May
“I know that this is not a politically easy thing to do. So I very much appreciate the leadership of the United States", says @DrTedros at @WHO presser on #covid19 about US support for #TRIPSwaiver “We urge other countries to follow their example.”
@DrTedros @WHO "We are in an unprecedented crisis that requires unprecedented action”, says @drtedros.
“The World Trade Organization provisions for IP waivers were designed precisely for a situation like this.
If we don't use them now, then when?"
@DrTedros @WHO This is important news:
"This afternoon, WHO gave emergency use listing to Sinopharm Beijing's #COVID19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality."
Read 18 tweets
Kai Kupferschmidt Profile picture
7 May
UK’s Joint Committee on Vaccination and Immunisation is now advising healthy adults younger than 40 “to receive an alternative to the Oxford/AstraZeneca vaccine – where available and only if this does not cause substantial delays in being vaccinated”.

gov.uk/government/new…
This is based on the fact that “the chances of a younger person becoming seriously ill with #COVID19 get smaller as infection rates increasingly come under control in the UK”.
@GretchenVogel1 and explored these trade-offs in risk and benefit here:

sciencemag.org/news/2021/05/w…
@GretchenVogel1 UK's regulator, the MHRA:
"The balance of benefits and risks is very favourable for older people but is more finely balanced for younger people and we advise that this evolving evidence should be taken into account when considering the use of the vaccine”
gov.uk/government/new…
Read 4 tweets
Kai Kupferschmidt Profile picture
4 May
So where are we on the rare clotting disorder linked to AZ and J&J shots? What do we know? How do risks and benefits compare? What does it mean long-term and around the world?
@GretchenVogel1 and I tried to answer some questions, thread to come in a bit.

sciencemag.org/news/2021/05/w…
First off:
This is complex and I‘m tired of people pretending it‘s all obvious.

So a few general points about the decisions that have to be made here:
They are
- local, but with global implications
- based on imperfect data in an evolving pandemic
- about individual decisions as well as population-level effects (and these two things can point in opposite directions)
Read 20 tweets
Kai Kupferschmidt Profile picture
23 Apr
In the US the Advisory Committee on Immunization Practices (ACIP) is meeting at the moment to discuss data on the rare clotting disorders seen after immunization with J&J’s #covid19 vaccine and to make recommendations on future use of the vaccine.
I’ll tweet along a bit.
Outcomes from the rare clotting disorders are likely to improve from "recognition among physicians also recognition in the public that if you develop a severe headache, severe abdominal pain that you really need to see your doctor", says @mstreif1.
@mstreif1 As of 21 April, 15 confirmed cases of the rare clotting disorder (here called TTS, Thrombosis with Thrombocytopenia Syndrome) after about 8 million vaccinations with J&J’s #covid19 vaccine, says @CDCgov's Tom Shimabukuro
Read 50 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

Like this author's thread?

Get emails when @kakape has new unrolls!

Check out other threads from @kakape!

Read all threads by @kakape

:(